Skip to main content

Table 3 Patient characteristics - knee

From: Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis

Study, Year

Number of patients TXA/C

Gender distribution % male TXA /C

Mean age TXA,C (SD or range)

Mean weight (kg) - TXA, C (SD or Range)

TBL - TXA,C (mL) (SD)

P Value

Number of patients requiring allogeneic transfusions (TXA, C)

P Value

 

TXA

C

TXA

X

TXA

C

TXA

X

TCA

C

 

TXA

C

 

Hiippala, 1995[27]

15

13

13

23

70 (56–82)

70 (63–78)

72 (10)

74 (10)

847 (356)

1549 (574)

<0.001

10

12

N/R

Benoni, 1996[17]

43

43

30

23

76 (7)

74 (7)

73 (14)

78 (16)

730 (280)

1410 (480)

<0.001

8

24

<0.001

Hiippala, 1997[12]

39

38

10

21

70 (7)

69 (5)

74 (13)

78 (12)

689 (289)

1509 (643)

< 0.0001

17

34

<0.0001

Jansen, 1999[2]

21

21

24

14

70.7 (62–80)

71.0 (64–84)

78.8 (11.0)

75.8 (12.4)

678 (352)

1419 (607)

<0.001

2

13

<0.001

Engel, 2001[42]

12

12

50

50

71 (9)

66 (11)

83 (12)

80 (13)

800 (295–1050)

865 (245–1370)

N/R

0

3

N/R

Ellis, 2001[36]

10

10

40

30

71 (5)

72 (8)

80 (12)

77 (15)

N/R

N/R

N/R

1

7

N/R

Tanaka, 2001[41] **

73

26

29, 32, 30

 

65 (59–70), , 65 (60–71), 65 (59–69)

65 (58–70)

60 (45–70), 60 (45–70), 60 (40–76)

61 (45 to 76)

720.4* (187.2)

1470 (264.8)

N/R

17, 16, 14

26

N/R

Veien, 2002[3]

15

15

73

93

70.5 (9.5)

69.5 (9.0)

78.7 (12.3)

74.3 (14.1)

409.7 (174.9)

761.7 (313.1)

<0.001

0

2

N/R

Good, 2003[18]

27

24

33

25

72 (46–83)

72 (50–84)

79 (13)

80 (13)

1045 (368.7 )

1426 (620.9 )

<0.001

3

14

<0.001

Zohar, 2004[35] ***

60

20

30, 20, 40

35

73 (8), 69 (7), 69 (10)

73 (7)

78 (12), 75 (13), 77 (13)

75 (12)

N/R

N/R

N/R

3, 2, 4

12

N/R

Orpen, 2006[5]

15

14

47

79

73 (95% CI 70–78)

69 (95% CI 63–74)

83 (95% CI 69–112)

77 (95% CI 58–96)

660 (317.6)†

726 (333.0) †

0.55

1

3

N/R

Camarasa, 2006[31]

35

60

26

20

73 (61–84)

72 (52–85)

N/R

1095 (473)

1784 (660)

N/R

N/R

N/R

Álvarez, 2007[6]

46

49

15

20

71 (9)

72 (7)

N/R

1301 (621)

1744 (804)

0.002

N/R

N/R

Molloy, 2007[19]

50

50

N/R

N/R

N/R

N/R

N/R

1225 (499)

1415 (416)

0.041

5

11

0.79

Kakar 2009[4]‡

12

12

25

33

62.4 (9.4),

66.2 (4.8)

67.9 (10.8)

63.4 (7.2)

160 (87)

270 (88)

<0.05

N/R

N/R

Wong, 2010[11] □

64

35

19, 42 □

37

67 (11.9), 63.9 (10.6)

68.4 (10.4)

82.0 (15.6), 81.8 (14.7)

87.9 (19.2)

1295 (353.7), 1208 (376.0)

1610 (378.6)

0.0001

1, 0

2

0.083

Ishida, 2011[43]

50

50

12

12

73.3 (5.0)

73.5 (6.1)

59.7 (9.0)

59.7 (10.1)

N/R

N/R

0

1

N/R

Sa-ngasoongsong, 2011[24]

24

24

78

82

69.0 (8.2)

69.2 (7.6)

N/R

N/R

206.3 (115.4)

385.1 (145.2)

<0.0001°

1

8

0.023

Roy, 2012[37]

25

25

40

36

66.04 (7.15)

66.56 (8.03)

N/R

N/R

**** 109.6 ± 71.54 + 401 ± 82.44

**** 194 ± 79.66 + 870 ± 201.04

N/R

2

7

Not Significant

  1. * - Weighted Mean Value7, † - Calculated from 95% CI, § Average, SD – Standard Deviation, C – Control group, TXA – Tranexamic acid group, - Median Value, DVT – deep venous thrombosis, ** (Patients received pre-op TXA, patients received intra-op TXA, patients received both pre + intra op TXA), ‡ - Unilateral TKA data reported only, □ - (Patients received 1.5 gm TXA, patients received 3 gm TXA), *** (Patients received TXA bolus + long IV, patients received TXA bolus + short IV, patients received oral TXA), N/R – not reported. **** Sum of per-operative and drain collection. ↑Patients received TXA prior to tourniquet deflation, an additional preoperative dose, an additional postoperative dose, all three doses, or locally.